Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Aryl piperazine suppresses cataractogenesis in a diabetic rat model via Nrf2/HO-1 signaling pathway

Xiu Wang¹, Congcong Tian², Chunning Zhao¹

¹Department of Ophthalmology, Qingdao Municipal Hospital, Qingdao, Shandong 266071; ²General Surgery Ward, Qingdao Municipal Hospital, Qingdao, Shandong 266000, China.

For correspondence:- Chunning Zhao Email: ChunningZhao167@gmail.com Tel:+8653288905363

Accepted: 25 October 2020 Published: 30 November 2020

Citation: Wang X, Tian C, Zhao C. Aryl piperazine suppresses cataractogenesis in a diabetic rat model via Nrf2/HO-1 signaling pathway. Trop J Pharm Res 2020; 19(11):2317-2322 doi: 10.4314/tjpr.v19i11.10

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the inhibitory potential of aryl piperazine on cataract formation in diabetic rats, and the underlying mechanism of action.

Methods: Sprague?Dawley rats (7-week-old) were divided into 7 groups: control rats, untreated diabetic rats, and five aryl piperazine treatment groups given the drug at doses of 1, 2, 5, 10 and 15 mg/kg. Diabetes was induced in the rats via injection of streptozocin (STZ) in citrate buffer at a dose of 65 mg/kg. An ophthalmoscope was used to evaluate cataract formation, while GlucoLeader was used for the measurement of blood glucose level.

Results: Aryl piperazine treatment significantly reduced blood glucose level from 6 to 12 weeks following administration of STZ, and prevented cataractogenesis in the diabetic rats (p < 0.05). Cataract score in the diabetic rats was also significantly decreased by aryl piperazine (p < 0.01). Aryl piperazine exposure reversed STZ-mediated decreases in antioxidant capacity (AOC) and glutathione (GSH) levels, enhanced glutathione peroxidase (GPX) activity and decreased malondialdehyde (MDA) levels in diabetic rats (p < 0.05). It suppressed the expressions of vascular endothelial growth factor (VEGF) and interleukin (IL)?1β in retinal tissues, while it upregulated the expressions of nuclear factor erythroid 2-related factor 2 (NRF2) and heme oxygenase (HO-1).

Conclusion: Aryl piperazine suppresses cataractogenesis and reduces cataract score in diabetic rats by targeting oxidative stress. Moreover, in retinal tissues of diabetic rats, aryl piperazine activates Nrf2/mHO?1 signaling pathway. Thus, aryl piperazine has a potential for use in the prevention of cataracts.

Keywords: Cataract, Hyperglycemia, Diabetic retinopathy, Oxidative stress, Glutathione